Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v3.19.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2018
Dec. 31, 2017
Current Assets    
Cash and cash equivalents $ 24,637,295 $ 4,515,398
Accounts receivable - project revenue and reimbursable project expenses 10,400
Other receivable from joint venture 93,253
Prepaid expenses and other current assets 36,745 70,067
Deferred financing cost, net 491,168
Total Current Assets 24,767,293 5,087,033
Other Assets    
Patent costs 1,577,421 1,367,692
Deferred financing cost, net 491,268
Total Other Assets 1,577,421 1,858,960
Total Assets 26,344,714 6,945,993
Current Liabilities    
Accounts payable and accrued liabilities 258,056 1,151,210
Investee losses in excess of investment 218,263
Total Current Liabilities 476,319 1,151,210
Commitments and contingencies - Note 6
Stockholders' Equity    
Common stock, $0.001 par value, 100,000,000 authorized, 32,862,090 shares and 12,737,703 shares issued and outstanding as of December 31, 2018 and 2017, respectively 32,863 12,738
Additional paid-in capital 129,329,674 93,602,539
Accumulated Deficit (103,497,622) (87,821,514)
Total Stockholders' Equity 25,868,395 5,794,783
Total Liabilities and Stockholders' Equity 26,344,714 6,945,993
Convertible Series A Preferred Stock [Member]    
Stockholders' Equity    
Preferred stock, $0.001 par value, 10,000,000 authorized shares: 813 1,020
Convertible Series B Preferred Stock [Member]    
Stockholders' Equity    
Preferred stock, $0.001 par value, 10,000,000 authorized shares: $ 2,667